- Home
- HAL vs ILMN Comparison
HAL vs ILMN Comparison
Compare HAL & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HAL
- ILMN
- Stock Information
- Founded
- HAL 1919
- ILMN 1998
- Country
- HAL United States
- ILMN United States
- Employees
- HAL N/A
- ILMN N/A
- Industry
- HAL Oilfield Services/Equipment
- ILMN Medical Specialities
- Sector
- HAL Energy
- ILMN Health Care
- Exchange
- HAL Nasdaq
- ILMN Nasdaq
- Market Cap
- HAL 22.8B
- ILMN 23.6B
- IPO Year
- HAL N/A
- ILMN 2000
- Fundamental
- Price
- HAL $26.84
- ILMN $135.21
- Analyst Decision
- HAL Strong Buy
- ILMN Buy
- Analyst Count
- HAL 18
- ILMN 17
- Target Price
- HAL $39.50
- ILMN $163.12
- AVG Volume (30 Days)
- HAL 8.9M
- ILMN 2.3M
- Earning Date
- HAL 01-22-2025
- ILMN 02-06-2025
- Dividend Yield
- HAL 2.53%
- ILMN N/A
- EPS Growth
- HAL N/A
- ILMN N/A
- EPS
- HAL 2.86
- ILMN N/A
- Revenue
- HAL $23,073,000,000.00
- ILMN $4,390,000,000.00
- Revenue This Year
- HAL $0.96
- ILMN N/A
- Revenue Next Year
- HAL $1.48
- ILMN $4.05
- P/E Ratio
- HAL $9.38
- ILMN N/A
- Revenue Growth
- HAL 0.93
- ILMN N/A
- 52 Week Low
- HAL $25.51
- ILMN $97.36
- 52 Week High
- HAL $41.56
- ILMN $156.66
- Technical
- Relative Strength Index (RSI)
- HAL 34.94
- ILMN 40.42
- Support Level
- HAL $25.51
- ILMN $130.31
- Resistance Level
- HAL $29.54
- ILMN $137.69
- Average True Range (ATR)
- HAL 0.82
- ILMN 5.31
- MACD
- HAL -0.35
- ILMN -1.10
- Stochastic Oscillator
- HAL 24.86
- ILMN 22.85
About HAL Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the largest pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the past two decades.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.